Portnoy Law Firm Announces Class Action on Behalf of Medpace Holdings, Inc. Investors
LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Medpace Holdings, Inc., (“Medpace” or the "Company") (NASDAQ: MEDP) investors of a class action on behalf of investors that bought securities between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”). Medpace investors have until June 8, 2026 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/medpace-holdings-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.
The Medpace class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Medpace consistently oversold Medpace’s projected book-to-bill ratio for fourth quarter 2025; (ii) Medpace knew or recklessly disregarded the impact that cancellations have on Medpace’s book-to-bill ratio; (iii) Medpace frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (iv) Medpace reassured investors that Medpace was not concerned about the lack of diversity in its pre-backlog; and (v) Medpace management stated that, despite the uptick in metabolic growth, Medpace’s upside was broad-based and not isolated to any handful of studies.
The Medpace class action lawsuit further alleges that on February 9, 2026, Medpace released fourth quarter 2025 earnings results revealing a book-to-bill ratio of 1.04, well below Medpace’s guidance. On this news, the price of Medpace common stock fell nearly 16%, according to the complaint.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
